Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

3.32
+0.15004.73%
Post-market: 3.360.0400+1.20%19:53 EDT
Volume:3.02M
Turnover:10.06M
Market Cap:286.22M
PE:-0.88
High:3.42
Open:3.15
Low:3.08
Close:3.17
52wk High:19.11
52wk Low:3.05
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.07
T/O Rate:4.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:1.72
PE(LYR):-1.05

Loading ...

EyePoint Reports Pivotal Phase 3 LUGANO Trial Results

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Morning Movers: EyePoint plummets following LUGANO trial results

TIPRANKS
·
Aug 17

EyePoint is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 17

EyePoint Tumbles After Experimental Eye Drug Misses Main Goal in Late-Stage Study

Reuters
·
Aug 17

EyePoint Eye Drug Misses Main Goal in Late-Stage Trial

Reuters
·
Aug 17

EyePoint Says Phase 3 Lugano Trial of Duravyu in Wet AMD Misses Primary Endpoint

Reuters
·
Aug 17

EyePoint - Primary Endpoint not Achieved in Full Dataset Due to Asymmetric Cohort

THOMSON REUTERS
·
Aug 17

EyePoint - Lucia Phase 3 Topline Data Expected Q4 2026; FDA Nda Submission Planned 1H 2027

THOMSON REUTERS
·
Aug 17

EyePoint Announces Topline Data from Lugano, the First of Two Pivotal Phase 3 Clinical Trials for Duravyu™ 2.7Mg in Wet Amd

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Achieves 42% Reduction in Treatment Burden vs Aflibercept

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Non-Inferior to Aflibercept in Ad Hoc Analysis Excluding 4% Asymmetric Cohort

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Observed to be Safe and Well Tolerated with Repeat Dosing

THOMSON REUTERS
·
Aug 17

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Aug 17

EyePoint Grants Inducement Stock Options for 14,600 Shares at $14.75 Each

Reuters
·
Aug 15

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 15

EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing

Simply Wall St.
·
Aug 14

EyePoint Pharmaceuticals (EYPT) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 12

EyePoint (EYPT) Completes Phase 3 Enrollment Early, Is The Stock Still Cheap?

Simply Wall St.
·
Aug 10

EyePoint is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 07